Optimizing the Development Strategy of Combination Therapy in Respiratory Medicine: From Isolated Airways to Patients.

Adrenergic beta-2 Receptor Agonists Benzoxazines Bronchodilator Agents Drug Combinations Humans Muscarinic Antagonists Pulmonary Disease, Chronic Obstructive Pulmonary Medicine Tiotropium Bromide
Asthma COPD Drug development Human isolated airways LABA/LAMA combination Respiratory Synergy Triple therapy

Journal

Advances in therapy
ISSN: 1865-8652
Titre abrégé: Adv Ther
Pays: United States
ID NLM: 8611864

Informations de publication

Date de publication:
12 2019
Historique:
received: 13 09 2019
pubmed: 28 10 2019
medline: 31 3 2020
entrez: 27 10 2019
Statut: ppublish

Résumé

The current recommendations for the treatment of chronic obstructive pulmonary disease (COPD) are pushing towards triple combination therapy based on the combination of an inhaled corticosteroid (ICS) associated with two bronchodilator agents. However, dual bronchodilation remains the cornerstone for the treatment of most COPD patients. Combining a long-acting β

Identifiants

DOI: 10.1007/s12325-019-01119-w PMID: 31654332 PMC: PMC6860506
pubmed: 31654332
doi: 10.1007/s12325-019-01119-w
pii: 10.1007/s12325-019-01119-w
pmc: PMC6860506
doi:

Substances chimiques

Adrenergic beta-2 Receptor Agonists 0
Benzoxazines 0
Bronchodilator Agents 0
Drug Combinations 0
Muscarinic Antagonists 0
olodaterol VD2YSN1AFD
Tiotropium Bromide XX112XZP0J

Banques de données

figshare
['10.6084/m9.figshare.9944756']

Types de publication

Journal Article Comment

Langues

eng

Pagination

3291-3298

Commentaires et corrections

Type : CommentOn

Références

COPD. 2017 Oct;14(5):526-532
pubmed: 28745522
Adv Ther. 2019 Apr;36(4):962-968
pubmed: 30843141
Chest. 2019 Apr;155(4):758-770
pubmed: 30660781
Respir Res. 2016 Jun 13;17(1):70
pubmed: 27296533
Eur J Pharmacol. 2017 Oct 5;812:147-154
pubmed: 28716723
Adv Ther. 2015 Sep;32(9):809-22
pubmed: 26404912
Respir Med. 2017 Mar;124:6-14
pubmed: 28284323
Eur J Pharmacol. 2015 Aug 15;761:168-73
pubmed: 25981302
Respir Res. 2018 Apr 12;19(1):65
pubmed: 29650006
Pharmacol Rev. 2006 Sep;58(3):621-81
pubmed: 16968952
Eur Respir Rev. 2017 Jan 17;26(143):
pubmed: 28096283
Curr Opin Pharmacol. 2018 Jun;40:95-103
pubmed: 29626716
Eur Respir J. 2018 Dec 13;52(6):
pubmed: 30309975
Int J Clin Pharmacol Ther. 2016 Jun;54(6):405-15
pubmed: 27049057
Eur J Pharmacol. 2014 Dec 15;745:135-43
pubmed: 25446566
Pulm Pharmacol Ther. 2015 Jun;32:15-23
pubmed: 25899618
Clin Pharmacol Drug Dev. 2016 Mar;5(2):109-17
pubmed: 27138024
J Vet Pharmacol Ther. 2018 Aug;41(4):546-554
pubmed: 29582435
Respir Med. 2017 Aug;129:189-198
pubmed: 28732830
Expert Rev Respir Med. 2018 Apr;12(4):261-264
pubmed: 29451042
Respir Med. 2016 Mar;112:65-74
pubmed: 26797016
Pulm Pharmacol Ther. 2016 Feb;36:1-9
pubmed: 26656790
Chest. 2016 May;149(5):1181-96
pubmed: 26923629
Int J Chron Obstruct Pulmon Dis. 2017 Dec 05;12:3469-3485
pubmed: 29255354
COPD. 2015 Apr;12(2):175-81
pubmed: 25222881
J Pharmacol Exp Ther. 2013 Sep;346(3):414-23
pubmed: 23766543
Pulm Pharmacol Ther. 2019 Jun;56:39-50
pubmed: 30876907
Clin Pharmacokinet. 2014 Jul;53(7):637-48
pubmed: 24756395
Respir Med. 2015 Oct;109(10):1305-11
pubmed: 26303336

Auteurs

Luigino Calzetta (L)

Unit of Respiratory Medicine, Department of Experimental Medicine, University of Rome "Tor Vergata", Rome, Italy. luigino.calzetta@uniroma2.it.
ORCID: 0000-0003-0456-069X

Maria Gabriella Matera (MG)

Unit of Pharmacology, Department of Experimental Medicine, University of Campania "Luigi Vanvitelli", Naples, Italy.

Mario Cazzola (M)

Unit of Respiratory Medicine, Department of Experimental Medicine, University of Rome "Tor Vergata", Rome, Italy.

Paola Rogliani (P)

Unit of Respiratory Medicine, Department of Experimental Medicine, University of Rome "Tor Vergata", Rome, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Effets physiologiques des médicaments › Agents neuromédiateurs › Agents adrénergiques › Agonistes adrénergiques › Agonistes bêta-adrénergiques › Agonistes des récepteurs béta-2 adrénergiques › Optimizing the Development Strategy of...
questionsmedicales.fr › Composés hétérocycliques › Composés hétérocycliques à cycles fusionnés › Composés hétérobicycliques › Benzoxazines › Optimizing the Development Strategy of...
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Agents de l'appareil respiratoire › Antiasthmatiques › Bronchodilatateurs › Optimizing the Development Strategy of...
questionsmedicales.fr › Préparations pharmaceutiques › Association médicamenteuse › Optimizing the Development Strategy of...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Optimizing the Development Strategy of...
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Effets physiologiques des médicaments › Agents neuromédiateurs › Agents cholinergiques › Antagonistes cholinergiques › Antagonistes muscariniques › Optimizing the Development Strategy of...
questionsmedicales.fr › États, signes et symptômes pathologiques › Processus pathologiques › Caractéristiques de la maladie › Maladie chronique › Broncho-pneumopathie chronique obstructive › Optimizing the Development Strategy of...
questionsmedicales.fr › Professions de santé › Médecine › Médecine interne › Pneumologie › Optimizing the Development Strategy of...
questionsmedicales.fr › Composés hétérocycliques › Composés hétérocycliques, cycle ponté › Tropanes › Dérivés de la scopolamine › Bromure de tiotropium › Optimizing the Development Strategy of...